Company Interview / Little Green Pharma's "transformational" merger

Chief executive Paul Long of Little Green Pharma highlights the recent merger between Little Green Pharma and Cannatrek, which aims to create one of the largest pure play cannabis companies globally. Long outlines that the merged entity will see Cannatrek holding 60.5% and Little Green Pharma 39.5% of the fully diluted capital. The move is driven by the need for consolidation in Australia's increasingly competitive medicinal cannabis market, which now features over 1,700 products. Long points out that Cannatrek’s leading flower-based product dominates the Australian market, surpassing competitors significantly in sales volume.

The merger brings a substantial cash injection and is expected to boost both EBITDA and overall scale, giving Little Green Pharma the resources to accelerate its expansion in the European market. Long identifies vertical integration and strategic supply sourcing from facilities such as Shepparton, Denmark, and Busselton as potential avenues to enhance profitability and operational synergies.

Long also addresses the critical role of medical education to differentiate products under Australia's strict TGA framework. Artificial intelligence is becoming a core focus for business processes, enabling efficiencies in regulatory compliance and data analysis. Long expresses confidence that industry tailwinds, including changes in US regulation, may soon be reflected positively in the share price of (ASX:LGP).

*paid partnership